Discover
MBRX
Moleculin Biotech, Inc.
2.69
7 x 2.55
2 x 3.27
bid
ask
-
0.10
3.58%
5 @ 07:43 AM
2.51 -0.18 (6.68%)
| Ytd | -18.73% | |
| 1y | -69.08% |
2.53
day range
2.75
1.79
52 week range
24.00
| Open | 2.59 | Prev Close | 2.79 | Low | 2.53 | High | 2.75 | Mkt Cap | 14.35M |
| Vol | 664.37K | Avg Vol | 495.83K | EPS | -16.16 | P/E | N/A | Forward P/E | -0.29 |
| Beta | 1.86 | Short Ratio | 0.36 | Inst. Own | 15.34% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-08 | 50-d Avg | 2.58 | 200-d Avg | 5.44 | 1yr Est | 18.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-08 | 2024-09 | -2.44 | -2.09 | 0.35 | 14.34% |
| 2024-08-13 | 2024-06 | -2.1 | -2.23 | -0.13 | -6.19% |
| 2024-05-10 | 2024-03 | -3.59 | -2.02 | 1.57 | 43.73% |
| 2024-03-22 | 2023-12 | -3 | N/A | N/A | N/A |
| 2023-11-13 | 2023-09 | -3.15 | -2.85 | 0.3 | 9.52% |
| 2023-08-11 | 2023-06 | -4.2 | -3 | 1.2 | 28.57% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-12 | Maxim Group | Upgrade | Buy | Buy |
| 2024-04-12 | Roth MKM | Upgrade | Buy | Buy |
| 2024-03-26 | Maxim Group | Upgrade | Buy | Buy |
| 2023-12-14 | HC Wainwright & Co. | Upgrade | Buy | |
| 2023-04-18 | Roth MKM | Upgrade | Buy | |
| 2023-03-24 | Oppenheimer | Upgrade | Outperform |
Profile
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-06-20 | FOSTER JONATHAN P. | Chief Financial Officer | 11.36K | Conversion of Exercise of derivative security |
| 2023-12-25 | GEORGE ROBERT E | Director | 14.66K | Purchase |
| 2024-07-01 | KLEMP WALTER V | Chief Executive Officer | 57.04K | Conversion of Exercise of derivative security |
| 2024-06-20 | PICKER DONALD H | Officer | 8.00K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Armistice Capital, LLC | 290.00K | 501.70K | 9.09% |
| 2024-09-29 | Vanguard Group Inc | 71.40K | 123.53K | 2.24% |
| 2024-09-29 | LPL Financial LLC | 36.10K | 62.46K | 1.13% |
| 2024-09-29 | Geode Capital Management, LLC | 21.82K | 37.74K | 0.68% |
| 2024-09-29 | Blackrock Inc. | 12.48K | 21.58K | 0.39% |
| 2024-09-29 | Renaissance Technologies, LLC | 11.00K | 19.02K | 0.34% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 42.47K | 73.47K | 1.33% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 30.31K | 52.44K | 0.95% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 14.79K | 25.59K | 0.46% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 3.22K | 5.57K | 0.10% |
| 2024-10-30 | Fidelity Total Market Index Fund | 2.06K | 3.56K | 0.06% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 1.04K | 1.80K | 0.03% |
Split
| Split | Date |
|---|---|
| 1 : 25 | 2025-12-01 |
| 1 : 15 | 2024-03-22 |
| 1 : 6 | 2021-02-01 |